EGFR and non-small cell lung carcinoma: A recent study reported that brigatinib, an ALK and EGFR inhibitor, when used in combination with cetuximab, was effective in patients with EGFR-sensitizing mutation/T790M/cis-C797S-positive NSCLC (72, 130).